Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer’s disease agents

Sheunopa C. Mzezewa, Sylvester I. Omoruyi, Luke S. Zondagh, Sarel F. Malan, Okobi E. Ekpo and Jacques Joubert

Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Bellville, South Africa

ABSTRACT

Multitarget directed ligands (MTDLs) are emerging as promising treatment options for Alzheimer’s disease (AD). Coumarin derivatives serve as a good starting point for designing MTDLs due to their inherent inhibition of monoamine oxidase (MAO) and cholinesterase enzymes, which are complicit in AD’s complex pathophysiology. A preliminary series of 3,7-substituted coumarin derivatives were synthesised and evaluated for enzyme inhibitory activity, cytotoxicity as well as neuroprotective ability. The results indicated that the compounds are weak cholinesterase inhibitors with five compounds demonstrating relatively potent inhibition and selectivity towards MAO-B with IC₅₀ values between 0.014 and 0.498 ìM. Significant neuroprotective effects towards MPP⁺-compromised SH-SY5Y neuroblastoma cells were also observed, with no inherent cytotoxicity at 10 μM for all compounds. The overall results demonstrated that substitution of the phenylethoxy moiety at the 7-position imparted superior general activity to the derivatives, with the propargylamine substitution at the 3-position, in particular, displaying the best MAO-B selectivity and neuroprotection.

1. Introduction

Neurodegenerative diseases (NDs) are a group of cognitive and movement-related disorders resulting from neuronal loss in the brain. Alzheimer’s disease (AD) is the most prevalent ND with over 30 million diagnosed patients worldwide. Its symptoms are progressive and irreversible, initially characterised by recurring short-term memory loss which progresses to degeneration of higher cognitive functions such as decision making and language. Due to the nature of these symptoms, the disease comes at a great burden economically and socially. There is no singular cause or process that is responsible for this neurodegeneration, rather it is the result of different interlinked mechanisms, underpinned by genetic and environmental factors. This complex pathophysiology has made treatment difficult and only symptomatic relief is provided by the drugs currently available on the market.

Of the multiple theories underlying AD’s pathophysiology, the roles of oxidative stress, toxic amyloid-β (Aβ) plaques, and the cholinergic hypothesis have gained momentum in explaining the disease’s pathology and in guiding treatment options. The cholinergic hypothesis postulates that the symptoms present in AD (particularly cognitive decline and amnesia) can be linked to declining function in the cholinergic neurotransmitter system. The cholinergic system is modulated by the neurotransmitter acetylcholine, metabolised by acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the brain. The primary therapeutic approach has been to counter cholinergic depletion using acetylcholinesterase inhibitors (AChEIs). This has thus far been done by using the second-generation AChEIs such as donepezil, galantamine, and rivastigmine. The clinical application of these agents has demonstrated that cholinesterase inhibition leads to modest improvement in cognitive functions and neuroprotection.

Monoamine oxidase (MAO) is a membrane-bound flavoenzyme responsible for metabolising a variety of substrates throughout the body such as serotonin, dopamine, and benzylamine. It exists in two forms, namely MAO-A and MAO-B, with each isofrom having differing substrate selectivity and distribution throughout the body. The MAO-B enzyme is the major isofrom found in the brain, responsible for 80% of MAO activity in the brain. MAO-B has been implicated in the generation of neurotoxic free radicals and reactive oxygen species which trigger neuroinflammation and the apoptotic cascade in neurons. Studies have found that MAO-B enzyme activity increases with old age and correlates closely with disease progression, making it a target for AD treatment.

Dual inhibition towards the causative MAO and cholinesterase enzymes has been demonstrated to not only improve cognitive functions but also to achieve neuroprotection and subsequently halt disease progression. Multitarget directed ligands (MTDLs) provide researchers with a way to use a single drug agent to simultaneously target the mentioned set of enzymes. MTDLs are made by combining pharmacophoric groups with differing pharmacological activities into one molecule to achieve a synergistic therapeutic effect, whilst avoiding the pitfalls of polypharmacy. MTDLs are being explored for use in a variety of complex diseases such as cancer and malaria. Several promising MTDLs have been explored for use in AD including ASS234 and lodastig...
which are based on the dual inhibition of MAO and cholinesterases.\(^{23,24}\)

The coumarin scaffold has many intrinsic pharmacological properties and coumarin derivatives have shown promise as a starting point for MTDL design strategies due to its ease of functionalisation and inherent ChE and MAO inhibitory capacity.\(^{25–27}\) This study, therefore, aimed to further explore the potential of coumarin derivatives as MTDLs by designing and synthesising a small series of compounds that have substitutions of moieties known to enhance inhibition of the MAO and cholinesterase enzymes (Figure 2).

One such moiety is the benzylxoy moiety that has been found to enhance the selectivity and potency of the coumarin scaffold towards MAO-B\(^{28–30}\). To optimise the coumarins’ activity towards the target enzymes, a phenylethyl moiety instead of the benzylxoy moiety was attached to the coumarin scaffold in this case. This would ensure that the designed compounds are sufficiently elongated to potentially interact with AChE’s peripheral anionic and catalytic binding sites (also known as dual-site binding), whilst preserving MAO-B binding interactions.\(^{31}\)

Similarly, the incorporation of the carbamate moiety onto the coumarin scaffold was investigated as well for this study. Numerous studies have found that it confers significant ChE inhibitory effect into various molecules which incorporate it, including the promising MTDL ladostigil\(^{24,32–34}\). These selected moieties were to be incorporated at the 7-position of the scaffold, as substitutions at this position are most beneficial for MAO-B selectivity and inhibition.\(^{29,35,36}\)

Propargylamine, a moiety known for its capacity to confer neuroprotection and increase MAO inhibition was also selected to be substituted at position 3 to enhance the pharmacological profiles of the 7-substituted coumarins.\(^{37,38}\) Position 3 of the scaffold has previously been described to be beneficial in achieving dual-site binding in AChE’s active site, thus substitutions at this position would serve an important role in producing dual ChE/MAO inhibitors.\(^{38,39}\) These molecules (Figure 2) could have the potential to relieve the symptoms of AD, slow down disease progression and ultimately reduce the burden of the disease.

2. Materials and methods

2.1. Chemistry

2.1.1. General

All reagents used in the synthesis of the compounds were obtained from Sigma-Aldrich\(^{50}\) (Steinheim, Germany) and Industrial Analytical (RSA). All solvents used for reactions and chromatography were purchased from various commercial sources and unless mentioned used without further purification. All reactions were monitored for impurities and completion using thin layer chromatography performed on sheets of 0.20 mm thick aluminium silica gel (TLC Silica gel 60 F245 Merck KGaA) with various mobile phases using volume:volume ratios. Once the plates were developed, the spots were visualised using UV light (254 nm and 366 nm) or iodine vapour. Purification of the specified compounds was performed in glass columns filled with appropriate amounts of silica gel (0.063–0.200 mm/70–230 mesh ASTM, Macherey - Nagel, Duren, Germany) as the stationary phase and with mobile phases indicated for each compound. Nuclear magnetic resonance (NMR) spectroscopy, Fourier Transform Infra-red (FT-IR) spectroscopy, and High-resolution mass spectrometry (HR-MS) techniques were used to elucidate the structures of the compounds. \(^1^H\) and \(^{13}C\) NMR spectra were obtained using a Bruker Avance III HD Nanobay 400 MHz spectrometer (Rheinstetten, Germany) equipped with a 5 mm BBO probe at 333 K using standard 1D NMR pulse sequence. Tetramethylsilane (TMS) was used as internal standard and all chemical shifts are reported in parts per million (ppm) relative to its signal (\(\delta = 0\)) in either deuterated dimethyl sulfoxide (DMSO-d\(_6\)) or deuterated chloroform (CDCl\(_3\)). The following abbreviations are used to describe the multiplicity of signals: s – singlet; d – doublet; dd – doublet of doublets; t – triplet; m – multiplet. The IR data was obtained using a Perkin Elmer Spectrum 400 spectrometer (Waltham, USA) fitted with a diamond attenuated total reflectance (ATR) attachment linked to a computer system.

2.1.2. Synthesis of 7-hydroxy-3-methyl-2H-1-benzopyran-2-one (1)

A mixture of 2,4-dihydroxybenzaldehyde (7.2 mmol, 1.0 g), sodium propionate (15.6 mmol, 1.5 g), propionic anhydride (19.4 mmol, 2.5 ml), and piperidine (1 mmol, 0.1 ml) was refluxed for 6 h and then poured onto ice. The aqueous mixture was made acidic with 20 ml of a 0.1 N solution HCl and yielded a precipitate that was filtered and treated under stirring with concentrated H\(_2\)SO\(_4\) (2 ml). The resulting mixture was poured into ice again to afford a red-brown precipitate of the desired product 1.

Physical Properties: Yield: 60%. mp: 165 °C. \(^1^H\) NMR (400 MHz, DMSO-d\(_6\)):

\[
\begin{align*}
\delta & 7.72 (s, 1H), 7.42–7.40 (d, 1H, J = 8.5 Hz), 6.76–6.73
\end{align*}
\]

\[
\begin{align*}
&7.72 (s, 1H), 7.42–7.40 (d, 1H, J = 8.5 Hz), 6.76–6.73
\end{align*}
\]
(dd, 1H, J = 2.2, 8.4 Hz), 6.69–6.68 (d, 1H, J = 2.1 Hz), 2.02 (s, 3H).<ref>13C NMR (100 MHz, DMSC-d_{2}): δ 161.8, 160.2, 154.5, 140.1, 128.7, 120.0, 113.0, 111.8, 101.9, 16.5. HR-ESI [M + H]^+: calc. 175.0395, exp. 175.0398. FT-IR (ATR): ν_{max} (cm^{-1}) 3234, 2934, 1739, 1675, 1451.

### 2.1.3. Synthesis of 3-methyl-7-(2-phenylethoxy)-2H-1-benzopyran-2-one (1)

A microwave-compatible glass-vessel was charged with 200 mg (0.71 mmol) of 7-hydroxy-3-methyl-2H-1-benzopyran-2-one (1), 68 mg (2.8 mmol) NaH (80% dispersion in oil), and dissolved in 2H), 4.17 (t, 2H, J = 6.9 Hz), 3.82 (s, 2H), 3.52 (d, 2H, J = 4.2 Hz). The reaction vessel was stirred at room temperature for 4 h and the reaction was complete. The succinimide residue was filtered out. The solvent was removed in vacuo and the crude product was purified via flash column chromatography (mobile Phase; hexaneethylacetatechloroform, 4:4:1). An orange solid of compound 4 was obtained.

Physical Properties: Yield: 43%. mp: 101–105 °C. 1H NMR (400 MHz, CDCl_3): δ 7.70 (s, 1H), 7.43–7.27 (m, 6H), 6.86–6.83 (dd, 1H, J = 2.3, 8.58 Hz), 6.81–6.08 (d, 1H, J = 2.1 Hz), 4.41 (s, 2H), 4.25–4.21 (t, 2H, J = 7.0), 3.14–3.11 (t, 2H, J = 7.1). 13C NMR (100 MHz, CDCl_3): 142.2, 129.0, 128.9, 128.6, 128.6, 126.8, 121.7, 113.4, 112.7, 101.6, 102.2, 69.2, 69.1, 35.5, 35.5, 28.2. HR-ESI [M + H]^+: calc. 359.0283, exp. 359.0298. FT-IR (ATR): ν_{max} (cm^{-1}) 3029, 2918, 1707 1158, 698.

### 2.1.6. Synthesis of 3-(bromomethyl)-2-oxo-2H-1-benzopyran-7-yldiethylcarbamate (5)

N-Bromosuccinimide (323 mg, 1.81 mmol) was added to a suspension of 3-methyl-2-oxo-2H-1-benzopyran-7-yldiethylcarbamate (250 mg, 0.91 mmol) (3) in 9 ml CCl_4. Following this benzoyl peroxide (7%) (192 mg, 0.80 mmol) was added to the mixture. After heating at reflux for 15 h, the hot reaction mixture was filtered to remove the succinimide by-product. The solvent was removed in vacuo and the crude product was purified via flash column chromatography (Mobile Phase; DCM: hexane: ethyl acetate 43:1) to obtain a white solid.

Physical Properties: Yield: 15%. mp: 84–88 °C. 1H NMR (400 MHz, CDCl_3): δ 7.83 (s, 1H), 7.48–7.46 (d, 1H, J = 8.6 Hz), 7.15 (d, 1H, J = 1.9 Hz), 7.13–7.10 (dd, 1H, J = 2.1, 8.5 Hz), 4.42 (s, 2H), 3.45–3.38 (m, 4H), 1.23–1.20 (m, 1H). 13C NMR (100 MHz, CDCl_3): 154.6, 154.4, 141.6, 128.5, 124.3, 118.9, 116.0, 110.2, 42.4, 22.1, 40.6, 35.1, 28.9, 27.7, 14.3, 13.3. HR-ESI [M + H]^+: calc. 359.0341, exp. 359.0344. FT-IR(ATR): ν_{max} (cm^{-1}) 2979, 2920, 1615, 1246, 1147.

### 2.1.7. Synthesis of 7-(2-phenylethoxy)-3-((prop-2-yn-1-yl) amino)methyl-2H-1-benzopyran-2-one (6)

A mixture of 115 mg (0.32 mmol) of 3-(bromomethyl)-7-(2-phenylethox)-2H-1-benzopyran-2-one (5) and 441 mg (3.2 mmol) of K_2CO_3 was dissolved in 5 ml dried THF. Propargylamine (44 mg, 0.8 mmol) was added dropwise and the mixture was stirred at room temperature for 48 h. The K_2CO_3 was filtered off and the solvent was removed under reduced pressure. The resulting crude product was purified using column chromatography (Mobile Phase; hexane: ethyl acetate 2:1) and the product was obtained as a waxy amber solid.

Physical Properties: Yield: 30%. mp: wax. 1H NMR (400 MHz, CDCl_3): δ 7.70 (t, 1H, J = 11.8 Hz), 7.36–7.27 (m, 6H), 6.84–6.81 (dd, 1H, J = 2.4, 8.4 Hz), 6.80–6.78 (d, 1H, J = 2.2 Hz), 4.23–4.20 (t, 2H, J = 6.9 Hz), 3.82 (s, 2H), 3.52 (d, 2H, J = 2.4), 3.14–3.11 (t, 2H, J = 7.3 Hz), 2.28 (t, 1H, J = 2.4 Hz). 13C NMR (100 MHz, CDCl_3): 161.8, 161.7, 155.1, 140.5, 137.6, 128.9, 128.7, 128.6, 126.7, 122.3, 112.7, 112.7, 101.2, 80.8, 72.5, 69.2, 47.7, 3.4, 35.5. HR-ESI [M + H]^+: calc. 334.1443, exp. 334.1450. FT-IR(ATR): ν_{max} (cm^{-1}) 3284, 3027, 2922, 2853, 1706, 1237.

### 2.1.8. Synthesis of 2-oxo-3-((prop-2-yn-1-yl) amino) methyl)-2H-1-benzopyran-7-yl-diethylcarbamate (7)

A mixture of 114 mg (0.64 mmol) of N-bromosuccinimide, 150 mg (0.54 mmol) of 3-methyl-7-(2-phenylethoxy)-2H-1-benzopyran-2-one (2) and 33 mg (0.14 mmol) of benzoyl peroxide (75%) were dissolved in 7 ml CCl_4. The reaction vessel was stirred at room temperature for 7 h and once the reaction was complete the succinimide residue was filtered out. The solvent was removed in vacuo and the crude product was purified via flash column chromatography (mobile Phase; hexaneeethylacetatechloroform, 4:4:1). An orange solid of compound 4 was obtained.

Physical Properties: Yield: 43%. mp: 101–105 °C. 1H NMR (400 MHz, CDCl_3): δ 7.70 (s, 1H), 7.43–7.27 (m, 6H), 6.86–6.83 (dd, 1H, J = 2.3, 8.58 Hz), 6.81–6.08 (d, 1H, J = 2.1 Hz), 4.41 (s, 2H), 4.25–4.21 (t, 2H, J = 7.0), 3.14–3.11 (t, 2H, J = 7.1). 13C NMR (100 MHz, CDCl_3): 142.2, 129.0, 128.9, 128.6, 128.6, 126.8, 121.7, 113.4, 112.7, 101.3, 102.2, 69.3, 69.1, 35.5, 35.5, 28.2. HR-ESI [M + H]^+: calc. 359.0283, exp. 359.0298. FT-IR (ATR): ν_{max} (cm^{-1}) 3029, 2918, 1707 1158, 698.
propargylamine. The mixture was stirred at room temperature for 48 h following which the inorganic residue was filtered off after washing with THF. The resulting solution was concentrated in vacuo and purified using column chromatography (Mobile phase: DCM: hexane: ethyl acetate in a 20:1:1 ratio) and an off-white solid was obtained.

Physical Properties: Yield: 21%. mp: 124–126° C. 1H NMR (400 MHz, CDCl3): δ 7.72 (s, 1H), 7.46–7.44 (m, 1H), 7.13 (d, 1H, J = 2.0 Hz), 7.10–7.07 (dd, 1H, J = 2.2, 8.4 Hz), 3.83 (s, 2H), 3.50 (s, 2H), 3.45–3.38 (m, 4H), 2.26–2.25 (t, 1H, J = 2.1 Hz), 1.28–1.19 (m, 8H). 13C NMR (100 MHz, CDCl3): 161.2, 153.9, 153.8, 153.2, 140.7, 126.0, 118.1, 116.5, 109.9, 77.8, 74.5, 52.5, 42.9, 42.4, 29.7, 14.3, 13.3. HR-ESI [M + H]+: calc. 329.1496, exp. 329.1495. FT-IR(ATR): νmax (cm⁻¹) 2921, 2851, 1634, 1616, 1245.

2.2. Biological studies

2.2.1. Cholinesterases assay

Cholinesterase activity is determined using a modified colorimetric method first described by Ellman. The test compounds and positive control (donepezil) were dissolved in DMSO to prepare 10 mM stock solutions. The stock was then further diluted by factors of ten to produce solutions of 1 mM, 10 μM, 1 μM, and 0.1 μM which corresponds to concentrations of 100 μM, 10 μM, 1 μM, 0.1 μM, and 0.01 μM in the final reaction mixture. The test concentrations were stored in the refrigerator until the day of the assay. Trisma HCl buffer (50 mM, adjusted to pH 8 with 2 N NaOH) and potassium phosphate buffer (KH2PO3 100 mM, pH 7.4, 0.9% w/v NaCl) was prepared and refrigerated until further use. The enzyme stock solutions were prepared by dissolving 2.5 mg of enzyme in 33.33 ml of phosphate buffer to produce stock solutions of 0.075 mg/ml which were stored in aliquots at −80°C until use.

To investigate the reversibility of the observed MAO enzyme inhibition, time-dependent inhibition studies were carried out on compounds 6 and 7. Briefly, the recombinant human MAO-B (0.0075 mg/ml) enzyme was preincubated with either 6 or 7 for periods of 0, 15, 30, 60 min at 37°C. The concentration of inhibitor in these incubations was approximately twofold the measured I50 value for the inhibition of the MAO-B enzyme. Potassium phosphate buffer (100 mM, pH 7.4, made isotonic with NaCl) was used as the incubation medium. A final concentration of 300 mM kynuramine for MAO-B was then added to the preincubated enzyme preparations and the resulting 250 μl reactions were incubated at 37°C for 15 min. The reactions were terminated with the addition of 200 μl NaOH (2 N) and a volume of 600 μl distilled water was added to each reaction. The fluorescence of the MAO-B generated 4-hydroxyquinoline in the supernatant fractions was measured using a fluorescent microplate reader at an excitation/emission wavelength of 310 nm/410 nm. Time-dependent graphs were plotted against the relative fluorescent unit readings (RFU).
2.2.5. MTT assay

SH-SYSY cells were plated in growth medium in the flat bottom 96 well plates at a density of approximately 7500 cells/well. The cells were allowed to adhere to the plate surface for 24 h and following this their media were replenished with fresh media containing the test compounds at 10 μM, 50 μM and 100 μM concentrations dissolved in DMSO. Vehicle control cells were treated with DMSO, at a concentration similar to that of the highest concentration of the test compounds. Following an incubation period of 48 h, 10 μl of MTT solution (5 mg/ml) was added to each well. This was further incubated for 4 h and the formazan formed was solubilised with 100 μl of DMSO. The plates were read using a BMG Labtech Omega® POLARStar plate reader spectrophotometer (Ortenberg, Germany) to determine the absorbance recorded at a wavelength of 570 nm. The percentage cell viability was calculated relative to the vehicle control using the following formula:

\[
\text{Cell viability} = \left( \frac{\text{Absorbance of treated well}}{\text{Absorbance of untreated well}} \right) \times 100
\]

2.2.6. Neuroprotection studies

2.2.6.1. MPP⁺ induced neurotoxicity. SH-SYSY cells were seeded onto a 96-well plate in a growth medium at a density of 10,000 cells/well. Cells were pre-treated with test compounds at a concentration of 10 μM and thereafter 2000 μM MPP⁺ following a 2-h incubation period. Afterwards, cells were incubated for 24 h and MTT colorimetric assay was used to measure cell viability relative to untreated control. To determine the data’s statistical significance, the One-way ANOVA Turkey’s multiple comparison test was conducted on all experimental replicates using GraphPad Prism⁸ (San Diego, USA).

2.2.6.2. Amyloid-beta 25–35 induced neurotoxicity. Human neuroblastoma cells (SH-SYSY) were grown in a culture medium (DMEM/F-12) and supplemented with 10% foetal bovine serum. Prophylactically, 1% v/v of penicillin/streptomycin was added to the medium. Cells were maintained by incubation at 37 ºC with 5% carbon dioxide. All experiments were performed by seeding the cells into 24-well plates. Once confluent, the cells were then pre-treated with compounds 6 and 7 (10 μM) for 1 h, followed by Aβ 25–35 addition (20 μM) and incubated for 24 h. The untreated control cells were treated with DMEM which contained DMSO and were incubated in the same manner as the treated cells. After incubation for the set period of time the MTT colorimetric assay, as discussed under 2.2.5., was used to measure cell viability relative to untreated control. The level of significance was analysed using One-way ANOVA statistical analysis and expressed using the p-value.

2.3. Molecular modelling

2.3.1. AChE docking studies

Molecular Operating Environment (MOE) 2018 on a Windows platform was used for the docking studies. The crystal structure of the AChE enzyme was obtained from the PSLIO/PDB data bank co-crystallised with donepezil (Code: 1EVE). Prior to the studies the enzyme was first checked for missing atoms and bonds. Partial charges, ionisation state and hydrogens were added to the macro-molecular structure using the 3D protonation function in the MOE application. The co-crystallised ligand was then selected to identify which binding site to use as the pocket for docking. The prepared enzyme was then saved in this state for use in the docking studies. The test ligands were drawn using ChemSketch 2016 software, saved as MDL files (V3000) and prepared for docking by energy minimising them in MOE using the MMFF94 force field. A database of these compounds was created and docking performed. Poses were generated using Triangle Matcher placement method and rescored using the ASE scoring function. The best poses were visually inspected and binding interactions analysed. To confirm the accuracy of the protocol it was repeated three times and generated RMSD values <2 Å from the co-crystallised ligand. This showed that the protocol could correctly predict the binding orientations.

2.3.2. MAO docking studies

Docking of the ligands was performed with MOE 2018. The co-crystallised MAO enzymes were obtained from the PSLIO/PDB data bank with MAO-A co-crystallised with clorgiline (Code: 2BXS) and MAO-B co-crystallised with safinamide (Code: 2VSZ). Prior to the studies, the enzyme was first checked for missing atoms and bonds. Partial charges, ionisation state, and hydrogens were added to the macromolecular structure using the 3D protonation function in the application. The co-crystallised ligand was then selected to identify which binding site to use as the pocket for docking. The prepared enzyme was then saved in this state for use in docking studies. The test ligands were drawn using the ChemSketch 2016 software, saved as MDL files (V3000) and prepared for docking by energy minimising them in MOE using the MMFF94 force field. A database of these compounds was created and docking performed. Poses were generated using the Triangle Matcher placement method and rescored using the ASE scoring function. The best poses were visually inspected and binding interactions analysed. To confirm the accuracy of the protocol it was repeated three times and generated RMSD values <1.5 Å from the co-crystallised ligand. This showed that the protocol could correctly predict the binding orientations.

2.4. In silico pharmacokinetic and drug-likeness evaluation

To evaluate the drug-likeness and pharmacokinetic profiles of compounds 6 and 7, the SwissADME web tool (http://www.swissadme.ch/) was utilised. The structures were drawn using ChemSketch (2016) and saved as MDL molfiles. The files were converted to SMILES (simplified molecular-input line-entry system) format which were then input into the web tool and the pharmacokinetic parameters were generated.

3. Results and discussion

3.1. Chemistry

The synthesis of the compounds (Scheme 1) commenced with a Pechmann condensation of dihydroxybenzaldehyde to obtain 7-hydroxy-3-methyl-coumarin (1) which served as the base scaffold. This scaffold was chosen due to the ease of substitution that the –OH group at position 7 allows. Simultaneously, the poor reactivity of the 3-CH₃ group protects the scaffold from unwanted substitution reactions occurring during subsequent reactions. Compound 1 was then functionalised at position 7 via either an etherification reaction with 2-bromoethylbenzene (2) or carbamate formation with diethyl carbamate (3). The synthesis of both 2 and 3 was optimised with the use of microwave (MW) irradiation to assist these S₈N₂ reactions, following the failure of traditional
Table 1. Optimisation of reaction conditions using microwave-assisted methods for compounds 2 and 3.

| Compound | Conditions | Yield* |
|----------|------------|--------|
| 2        | Ethanol, NaH | 0%     |
|          | Stir at room temp., 11 h | 37%    |
|          | Acetonitrile, NaH | 37%    |
|          | MW @ 150 W, 80 °C, 5 h | 37%    |
| 3        | Dimethoxyethane, K2CO3 | 0%     |
|          | Stir at room temp., overnight | 9%     |
|          | Dimethoxyethane, K2CO3 | 9%     |
|          | Reflux, 12 h | 27%    |
|          | Acetonitrile, K2CO3 | 27%    |
|          | MW @ 150 W, 100 °C, 6 h | 65%    |
|          | Acetonitrile, K2CO3, TBAHSO4 | 65%    |
|          | MW @ 150 W, 100 °C, 2.5 h | 65%    |

*Percentage yield was calculated from the amount of 7-hydroxy-3-methyl-coumarin (1) used.

The results confirm that the initial substitutions to position 7 increased both the inhibitory capacity and MAO-B selectivity of the coumarin scaffold. The phenylethyloxy moiety conferred superior inhibition and selectivity when compared to the carbamate moiety in this regard (see Table 2). Incorporation of the
progylamine moiety appears to not only increase the derivatives' potency towards MAO-B, but also has the greatest influence on the compounds' selectivity. The 3-propargylamine derivatives 6 and 7 displayed between 130 and 206 times greater selectivity to MAO-B when compared to MAO-A. Together, these results show that whereas, compounds 2 was more active in the inhibition of MAO-B, compounds 6 and 7 showed better selectivity and this can be attributed to the addition of the propargylamine moiety.

### Table 2. In vitro biological activities of the synthesised and reference compounds.

| Compound | AChE IC₅₀ (µM) | BuChE IC₅₀ (µM) | MAO-A IC₅₀ (µM) | MAO-B IC₅₀ (µM) | SI MAO-B* (µM) | MPP⁺ neuroprotection* (10 µM) |
|----------|----------------|-----------------|-----------------|-----------------|---------------|------------------|
| Donepezil | 0.007          | 4.40            | n.d.            | n.d.            | n.d.          | n.d.             |
| Clorgiline | n.d.           | 33.40           | 16.36           | 20.4            | 24.85%        |
| Selegiline | n.d.           | 20.4            | 7.99            | 22.1            | 15.9%         |

*MAO-B selectivity index = IC₅₀(MAO-A)/IC₅₀(MAO-B). *Percentage neuroprotection values calculated as the difference between the final percentage cell viability of the test compound treated cell line and that of the MPP⁺ only treated cell line. n.d. = not determined

![Figure 3](image-url). (a) Diagrammatic representation of compound 1's lack of binding interactions with amino acids in MAO-A's active site. (b) 3D docking simulation showing 1 indicated in pink within the MAO-A active site.

3.2.2. MAO molecular modelling studies

3.2.2.1. MAO-A docking studies. Molecular Operating Environment (MOE) was used to perform docking studies with the test compounds in an attempt to shed light on the preliminary structure-activity relationships responsible for the results obtained in the assay. When the base scaffold, compound 1, was docked within the MAO-A active site it was observed that the coumarin nucleus simply enters the entrance cavity, with no significant binding interactions taking place (Figure 3). This lack of binding correlates to the compound's low activity observed in the assay. The docking simulations also confirmed that the superior activity of the 7-phenylethoxy derivatives arose from the phenylethoxy moiety allowing compounds 2 and 4 to assume orientations that occupy MAO-A's rounder-shaped substrate cavity better than the other compounds (Figure 4). By contrast, the 7-carbamate derivatives 3 and 5 are seen to only exhibit weak sidechain interactions with the Cys 323 residue (near the entrance of the catalytic site) and the oxygen atom on the carbamate moiety.

Figure 5 shows that the addition of the propargylamine scaffold produced molecules that are unable to fit into MAO-A's active site. Docking conformations of compounds 6 and 7 demonstrate that the molecules lack the flexibility to fit and subsequently interact with amino acids in the cavity's active site. This correlates with the relatively poor MAO-A inhibitory capacity of these compounds reported in the assays (Table 2).

3.2.2.2. MAO-B docking studies. Contrary to MAO-A, for MAO-B it can be observed that the coumarin nucleus 1 fits well into the entrance cavity, forming relatively stable π-H bonds between the aromatic ring and the amino acids Ile 199 and Leu 171 (Figure 6). This hydrogen bond with the Leu 171 residue on the fringe of the substrate cavity was observed and conserved for the rest of the compounds and may explain their selectivity towards MAO-B. The 7-phenylethoxy derivatives (particularly compound 2) good activity and selectivity can be attributed to the previously noted interactions with Leu 171 coupled with new stable π-H bonds which form between the phenylethyl moiety and the Ile 199 residue. This interaction is important as the Ile 199 residue is critical in forming part of the gating mechanism which allows access to MAO-B's substrate cavity²⁸. The 7-carbamate compounds retain the π-H interaction with Leu 171 which was first observed with 1, however, they lack the hydrogen bond with Ile 199 and this may account for their lower activity compared to their 7-phenylethoxy counterparts.

Similarly, in contrast to MAO-A, the elongated nature of the MAO-B active site allows for better accommodation of the 3-
It was observed that both compounds were able to interact with the crucial flavin adenine dinucleotide (FAD) cofactor to varying extents due to the inclusion of the propargylamine moiety. The FAD cofactor is essential for substrate catalysis and thus compounds that can come into close proximity or bind to this cofactor are known to inhibit the enzyme function to a greater extent. Compound 6 maintains the previously mentioned π–H bonding with Cys 172 as well as its propargylamine moiety orienting in close proximity to FAD. Compound 7’s propargylamine moiety forms crucial π–H bonds with the cofactor. From the low nanomolar IC₅₀ and high SI values displayed by these compounds, the importance of the propargylamine moiety can be seen in its ability to produce highly potent and selective inhibitors of MAO-B (Figure 7).

**3.2.3. MAO-B reversibility studies**

To determine the binding mode of the studied compounds on MAO-B, the time dependency of enzyme inhibition was measured. If the compounds form a covalent or irreversible adduct with the enzyme, a time-dependent reduction of enzyme activity would be expected. In this regard, the time-dependent inhibition of MAO-B by the most promising and selective MAO-B inhibitors namely 6 and 7, were evaluated (Figure 8). Briefly, recombinant human MAO-B was preincubated with the test compounds for periods of 0, 15, 30, and 60 min prior to starting the enzyme reaction and the residual rates of the MAO-B catalysed oxidation of kynuramine were measured. For this purpose, the concentrations of the test compounds chosen were approximately twofold the measured IC₅₀ values for the inhibition of the respective enzymes. Selegiline, an irreversible inhibitor of the MAO-B enzyme with a propargylamine functional group within its structure, was used as a reference compound. As shown in Figure 8, MAO-B enzyme activity was not reduced by the propargylamine containing coumarins 6 and 7 with increased preincubation time. However, selegline shows a clear time-dependent reduction in activity confirming its irreversible mode of inhibition. This indicates that both compounds 6 and 7 can be considered as reversible inhibitors of MAO-B and that the propargylamine function does not bind to the FAD co-factor covalently as is the case in selegiline.
benefit of reversible MAO inhibitors is that they can possibly reduce the toxicity of the molecules as the effect of the inhibitor can be reversed when the drug is withdrawn\(^45,46\).

### 3.2.4. Cholinesterase inhibition studies

The AChE and BuChE inhibitory capacity of the compounds was tested using a modified method of the assay developed by Ellman\(^47\). The results of the assay showed that generally, the compounds had low inhibitory activity against AChE up to a 100 \(\mu M\) concentration. The 3-bromoethyl derivative 5 demonstrated the best activity exhibiting 49\% enzyme inhibition at the aforementioned concentration and an IC\(_{50}\) value of \(\sim 108\) \(\mu M\). The results illustrate that substitution with either the carbamate or phenylethyl moieties at position 7 does not solely confer significant AChE inhibitory activity to the scaffold, as compounds 2 and 3 have similar activity to 1. However, the \(\alpha\)-bromination of the methyl at position 3 to produce -3-CH\(_2\)Br demonstrated a significant increase in the compound’s inhibitory capacity. As observed with compounds 6 and 7, the 3-propargylamine derivatives had diminished activity compared to the 3-bromomethyl of compound 5. The increased length of these 3-propargylamine derivatives was expected to correlate with an increase in inhibitory activity, however, their activity was only marginally better than the shorter 3-methyl derivatives (2 and 3).

Interestingly, the test compounds were more active against BuChE than AChE with higher percentage inhibitions at a 100 \(\mu M\) concentration. Compounds 1 and 5 were the most active inhibitors, with IC\(_{50}\) values of 20.25 \(\mu M\) and 23.27 \(\mu M\) respectively. Compound 1, having the lowest IC\(_{50}\) value, demonstrates that neither of the substitutions at the 7-position enhanced the latent BuChE inhibitory capacity of the coumarin scaffold. Compound 5 was the exception having an IC\(_{50}\) close to that of 1, however,
there is no significant correlation between the nature of the substitution and the compound’s resultant BuChE inhibitory activity. Based on their higher overall inhibition towards BuChE, the tested compounds can be classified as weakly selective BuChE inhibitors. The compounds’ selectivity may be ascribed to them having stronger binding interactions with the higher density of hydrophobic amino acids lining the active-site gorge of BuChE. The larger volume of BuChE’s active site may also allow the enzyme the ability to accommodate the compounds better than in AChE.

3.2.5. Cholinesterase molecular modelling studies
The AChE enzyme active site is an ellipsoid-shaped gorge, consisting of two main sites termed the peripheral anionic site (PAS) (at the entrance of the active site) and the catalytic binding site (CAS) containing the catalytic triad. The PAS is made up of largely aromatic amino acids such as Trp 279 and is responsible for guiding and stabilising substrates in the active site. The initial predictions from literature anticipated that the coumarin nucleus will sit in the PAS of the enzyme and the various substituents interact with the CAS and catalytic triad. The best-ranked docking results show that instead, the initial substitutions at position 7 performed in compounds 2 and 3 orients the coumarin nucleus away from the PAS and towards the CAS (Figure 9). When the molecules are oriented in this way, neither compound is able to form favourable interactions with amino acids in either of these regions.

The improved inhibitory capacity of compounds 4 and 5 can be attributed to how the -CH$_2$Br group forms π–H interactions with Trp 84 and the π–π stacking between the aromatic region of the coumarin and Phe 330 (Figure 10). Both of these are key residues for substrate binding in the CAS. It can be hypothesised that the electron-withdrawing effect caused by bromine may have led to more stable interactions with the aromatic Trp 84 residue and was responsible for these compounds’ superior inhibitory activities. Substitution with propargylamine in the same position in derivatives 6 and 7 resulted in added length to the molecules, however, this altered the conformation of the compounds in the active site. As a result, the binding interactions which had been demonstrated with 4 and 5 were disrupted (Figure 11).

3.2.6. Cytotoxicity studies
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to assess the cytotoxicity of test compounds following their exposure to the SH-SYSY neuroblastoma cells at concentrations of 10 lx00B5;M; 50 lM; and 100 lM using neuroblastoma SH-SYSY cells. The results show that in general, the exposure to the test compounds led to a concentration-dependent decrease in the SH-SYSY cell viability (Figure 12). With the majority of the compounds, this decrease in viability was not statistically significant (p > 0.05) at the 50 lM and 100 lM concentrations. At 10 lM the compound’s cytotoxic effect is diminished and can be seen to cause a slight favourable increase in cell viability similar to the untreated control. The 3-bromomethyl derivatives 4 and 5 displayed the most concentration-related cytotoxicity, with a significant reduction in cell viability at 50 lM and 100 lM. Compound 4’s profile was significantly better with 65% and 7% survival at 50 lM and 100 lM, respectively, compared to a 0% survival rate at the same concentrations for 5. The 3-bromomethyl substitution can be assumed to underpin this cytotoxicity and this is in agreement with previous studies describing the general cytotoxicity of halogen-containing coumarin derivatives. This cytotoxicity is mitigated at the lower 10 lM concentration.

3.2.7. Neuroprotection studies
The neurotoxin 1-methyl-4-phenyl pyridinium (MPP$^+$) is widely known to induce an apoptotic cascade in neurons and is thus used to induce neurodegeneration in various in vitro and in vivo models of NDs. In this study, the neuroprotective nature of compounds was determined using an in vitro MTT assay based on their ability to rescue SH-SYSY neuroblastoma cells from this MPP$^+$ induced in neurotoxicity.

The SH-SYSY cells were pre-treated with 10 lM of the test compounds for 2 h followed by the addition of 2000 lM of MPP$^+$. The 10 lM concentration was selected as the compounds did not cause any cytotoxicity at this concentration, thus it would be a fair representation of their neuroprotective effect. The treated cells displayed higher survival counts compared to the MPP$^+$-treated cells (Figure 13), which indicates that the compounds provided neuroprotection to the cells. The cells exposed to the test...
compounds increased significantly increased ($p < 0.05$) the survival rate (15–36%) when compared to the MPP$^+$ only treated group. The nature of the moiety at position 7 does not seem to influence this neuroprotection greatly, as there was no significant trend observed between the 7-benzeloxy and 7-carbamate derivatives. However, as expected, the propargylamine derivatives exhibited the highest neuroprotective capability as reported in the literature.\textsuperscript{24,56,57} Cell lines treated with compounds 6 and 7 had 92% and 85% survival rates respectively, further demonstrating the moiety's significance in neuroprotection.

The general neuroprotective profile of the compounds may also suggest that the observed neuroprotection is independent of their enzyme inhibitory capabilities, as all compounds performed fairly similarly despite having different enzyme inhibitory profiles. As described in the literature, coumarin derivatives may possess inherent anti-inflammatory, anti-apoptotic and antioxidant effects which, together with the MAO-inhibition effects of the test compounds, increased significantly increased ($p < 0.05$) the survival rate (15–36%) when compared to the MPP$^+$ only treated group.

The nature of the moiety at position 7 does not seem to influence this neuroprotection greatly, as there was no significant trend observed between the 7-benzeloxy and 7-carbamate derivatives. However, as expected, the propargylamine derivatives exhibited the highest neuroprotective capability as reported in the literature.\textsuperscript{24,56,57} Cell lines treated with compounds 6 and 7 had 92% and 85% survival rates respectively, further demonstrating the moiety's significance in neuroprotection.

The general neuroprotective profile of the compounds may also suggest that the observed neuroprotection is independent of their enzyme inhibitory capabilities, as all compounds performed fairly similarly despite having different enzyme inhibitory profiles. As described in the literature, coumarin derivatives may possess inherent anti-inflammatory, anti-apoptotic and antioxidant effects which, together with the MAO-inhibition effects of the test compounds, increased significantly increased ($p < 0.05$) the survival rate (15–36%) when compared to the MPP$^+$ only treated group.

The general neuroprotective profile of the compounds may also suggest that the observed neuroprotection is independent of their enzyme inhibitory capabilities, as all compounds performed fairly similarly despite having different enzyme inhibitory profiles. As described in the literature, coumarin derivatives may possess inherent anti-inflammatory, anti-apoptotic and antioxidant effects which, together with the MAO-inhibition effects of the test compounds, increased significantly increased ($p < 0.05$) the survival rate (15–36%) when compared to the MPP$^+$ only treated group.
compounds may synergistically counter the MPP\(^+\) induced apoptosis\(^{29,35,36,58}\). The results give an indication that the compounds would be tolerated well by neurons at or below the 10 \(\mu\)M concentration and most importantly, potentially ameliorate the neurodegeneration associated with the progression of AD, and/or other neurodegenerative disorders.

The accumulation of extracellular A\(\beta\) plaques has been marked as one of the pathological hallmarks of neurotoxicity associated with AD\(^{59-61}\) and coumarin moieties have previously shown to inhibit A\(\beta\) plaque formation and A\(\beta\) induced neurotoxicity\(^{62,63}\). To further explore the neuroprotective potential of the propargylamime-containing coumarin derivatives 6 and 7, their ability to curb neurotoxicity induced by the amyloid-\(\beta\) (A\(\beta\)) protein was thus assessed according to the method described in the experimental section. In order to evaluate these compounds, the A\(\beta\) 25–35 peptide fragment was used to induce neurotoxicity in SH-SY5Y cells. A\(\beta\) 25–35 has been reported to be the actual biological active site of A\(\beta\) responsible for the peptide’s neurotoxic ability and has been used in similar models of neurodegeneration in previous studies\(^{11-14}\).

The exposure of A\(\beta\) 25–35 on the SH-SY5Y cells for 24 h exhibited significant (\(p < 0.01\)) detrimental effects, when compared to the control, with a loss of cell viability of between 30% and 45% in five independent experiments conducted in triplicate. This reduction in cell viability in SH-SY5Y cells after A\(\beta\) 25–35 treatment was also reported in previous studies\(^{64,65}\). As the addition of A\(\beta\) 25–35 in SH-SY5Y cells precipitates apoptosis\(^{66,67}\), the neuroprotective activity of 6 and 7 on mitigating cellular apoptosis was examined at concentrations between 10 \(\mu\)M and 100 \(\mu\)M. Unfortunately, the compounds, at all concentrations, did not show any significant ability to mitigate the cytotoxic effects caused by A\(\beta\) 25–35. The significant neuroprotection observed in the MPP\(^+\) assay, however, highlights the need for further neuroprotective and mechanistic studies. This will shed light on the potential of these compounds as neuroprotective agents in not only AD but other neurodegenerative disorders such as Parkinson’s disease (PD) as well.

### 3.2.8. In silico pharmacokinetic and drug-likeness evaluation

In addition to displaying the relevant biological activities, it is equally important for ideal drug candidates to have low toxicity and access to their therapeutic target. Computer models used in the discovery phase with online tools such as SWISSADME are used to provide an early estimation of drug candidates’ ADME, drug-likeness, and pharmacokinetic properties. This decreases the fraction of pharmacokinetics-related failure in the clinical phases\(^{58,69}\). The most promising drug candidates from this study, compounds 6 and 7, were assessed for their drug-likeness and pharmacokinetic profiles using the SWISSADME web tool.

A bioavailability radar (Figure 14) was generated, which provides a graphical snapshot of the drug-likeness parameters of an orally available bioactive drug. A range for each parameter was defined and depicted as a pink area on the radar plot. The parameters are defined as lipophilicity (LIPO; \(-0.7 \leq \text{XLOGP3} \leq +5.0\));
Based on these results the compounds could serve as drug-like entities by pharmaceutical companies, especially compounds 6 and 7 conducted the MAO-B reversibility study; S.I.O. performed the syntheses, MAO and ChE assays; L.S.Z. conceived and designed the study and experiments. J.J. and S.C.M. conceived and designed the study and experiments. We are grateful to Prof. Edith Antunes for assisting in the NMR experiments.

4. Conclusions

The objectives of this study were to synthesise a number of neuroprotective coumarin derivatives substituted with various privileged moieties for potential cholinesterase and MAO inhibitory activities. The compounds were synthesised and characterised, and biological evaluations showed that both compounds have high predicted intestinal absorption and BBB (blood–brain barrier) permeability (Table 3)71. BBB permeability is of utmost importance to the agents’ mechanism of action as they need to cross the barrier to inhibit the action of enzymes in the brain as well as offer neuroprotection to affected cells. The Abbot Bioavailability Score predicted the compounds to have high oral bioavailability and they are non-substrates of the permeability glycoprotein (P-gp). P-gp is an efflux pump in the GIT which pumps out xenobiotics (including drugs) away from the BBB and intestinal epithelium, reducing their bioavailability72. Finally, the compounds were found to comply with the computational filters developed for identifying drug-like entities by pharmaceutical companies, Lipinski (Pfizer), Ghose (Amgen), Egan (Pharmacia), Veber (GSK), and Muegee (Bayen)73,74. Based on these results the compounds could serve as promising lead compounds for AD.

Acknowledgement

We are grateful to Prof. Edith Antunes for assisting in the NMR experiments.

Author contributions

J.J. and S.C.M. conceived and designed the study and experiments. S.C.M. performed the synthesis, MAO and ChE assays; L.S.Z. conducted the MAO-B reversibility study; S.I.O. performed the cytotoxicity and neuroprotection studies. S.C.M. and J.J. analysed the NMR, IR, MS, and biological data; SCM and J.J. performed and analysed the molecular modelling. O.E.E. provided the facilities and consumables for the neuroprotection and cytotoxicity assays. J.J. and S.F.M. provided supervisory and funding support. S.C.M. prepared the paper and all authors edited the final draft. All authors have read and agreed to the published version of the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was financially supported by the University of the Western Cape as well as the National Research Foundation of South Africa.

ORCID

Sarel F. Malan http://orcid.org/0000-0002-1640-6457
Jacques Joubert http://orcid.org/0000-0003-0378-7091

Table 3. In silico drug-likeness properties of compounds 6 and 7

| Compounds | BBBa | GIAb | P-gpc | Lipinski | Ghose | Veber | Egan | Muegee | Bio. Scored |
|-----------|------|------|-------|----------|-------|-------|------|--------|------------|
| 6         | Yes  | High | No    | Yes      | Yes   | Yes   | Yes  | Yes    | Yes 0.55   |
| 7         | Yes  | High | No    | Yes      | Yes   | Yes   | Yes  | Yes    | Yes 0.55   |

aBBB: Blood brain barrier permeant; bGIA: Gastrointestinal absorption; cP-gp: P-glycoprotein substrate; dBio. Score: Abbot bioavailability score (probability of >10% bioavailability).

References

1. Takeda S. Progression of Alzheimer’s disease, tau propagation, and its modifiable risk factors. Neurosci Res 2019;141:36–42.
2. Vajda F. Neuroprotection and neurodegenerative disease. In: Alzheimer’s disease. Current clinical neurology. Totowa (NJ): Humana Press; 2004: 235–243.
3. Brunströmr HR, Englund E. Cause of death in patients with dementia disorders. Euro J Neurol 2009;16:488–92.
4. Kasper JD, Freedman VA, Spillman BC, Wolff JL. The disproportionate impact of dementia on family and unpaid caregiving to older adults. Health Aff 2015;34:1642–9.
5. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Therap Adv Neurol Disord 2013;6:19–33.
6. Swerdlow R. Pathogenesis of Alzheimer’s disease. Clin Interv Aging 2007;2:347–59.
7. Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol 2011;4:293–8.
8. Kim D, Baik S, Kang S, et al. Close correlation of monoamine oxidase activity with progress of Alzheimer’s disease in mice, observed by in vivo two-photon imaging. ACS Central Sci 2016;2:967–75.
9. Tönnes E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J Alzheimers Dis 2017;57:1105–21.
10. García-Ayllón MS, Riba-Llena I, Serra-Basante C, et al. Altered levels of acetylcholinesterase in Alzheimer plasma. PLoS One 2010;5:e8701.

11. Hangya B, Ranade S, Lorenz M, Kepecs A. Central cholinergic neurons are rapidly recruited by reinforcement feedback. Cell 2015;162:1155–68.

12. Prado V, Janickova H, Al-Onaizi M, Prado M. Cholinergic circuits in cognitive flexibility. Neuroscience 2017;345:130–41.

13. Colovic M, Krstic D, Lazarevic-Pasti T, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013;11:315–35.

14. Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ 2014;15:791–800.

15. Linton A. The benefits of cholinesterase inhibitors: managing the behavioral and neuropsychiatric symptoms of Alzheimer’s disease. J Gerontol Nurs 2005;31:4–9.

16. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharmacol Res 2013;36:375–99.

17. Schedin-Weiss S, Inoue M, Hromadkova L, et al. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Alzheimer’s Res Ther 2017;9:57.

18. Blennow K, Mattsson N, Schöll M, et al. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015;36:297–309.

19. Riederer P, Danielczyk W, Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer’s disease. Neurotoxicology 2004;25:271–7.

20. Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (review). Mol Med Rep 2014;9:1533–41.

21. Chimenti F, Bolasco A, Secci D, et al. Investigations on the 2-thiazolylhydrazine scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors. Bioorg Med Chem 2010;18:5715–23.

22. Tibon N, Ng C, Cheong S. Current progress in antimalarial pharmacotherapy and multi-target drug discovery. Euro J Med Chem 2020;188:111983.

23. Marco-Contelles J, Unzeta M, Bolea I, et al. ASS234, as a new multi-target directed propargylamine for Alzheimer’s disease. Med Chem Commun 2012;3:213–8.

24. Schneider L, Geffen Y, Rabinowitz J, et al. Low-dose ladostigil for mild cognitive impairment: a phase 2 placebo-controlled clinical trial. Neurology 2019;93:e1474–84.

25. Santana L, González-Díaz H, Quezada E, et al. Quantitative structure–activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 2008;51:6740–51.

26. Stefanachi A, Leonetti F, Pisani L, et al. Coumarin: a natural, privileged and versatile scaffold for bioactive compounds. Molecules 2018;23:250.

27. Pisani L, Farina R, Soto-Otero R, et al. Searching for multi-targeting neurotherapeutics against Alzheimer’s: discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-chromen-2-one structural motif. Molecules 2016;21:362.

28. Brühlmann C, Ooms F, Carrupt P, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001;44:3195–8.

29. Joubert J, Foka G, Repsold B, et al. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Euro J Med Chem 2017;125:853–64.

30. Pérez V, Marco JL, Fernández-Alvarez E, Unzeta M. Relevance of benzoxyl group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 1999;127:869–76.

31. Catto M, Nicolotti O, Leonetti F, et al. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. J Med Chem 2006;49:4912–25.

32. Darvesh S, Darvesh KV, Mcdonald RS, et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem 2008;51:4200–12.

33. Bak A, Kozik V, Kozakiewicz D, et al. Novel benzene-based carbamates for AChE/BChE inhibition: synthesis and ligand/structure-oriented SAR study. Int J Mol Sci 2019:20:1524.

34. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994:43:219–25.

35. Farina R, Pisani L, Catto M, Nicolotti, et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J Med Chem 2015;58:5561–78.

36. Soto-Ortega DD, Murphy BP, Gonzalez-Velasquez FJ, et al. Inhibition of amyloid-β aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. Bioorg Med Chem 2011;19:2596–602.

37. Naol M, Maruyama W, Youdum M, et al. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 2003;11:175–81.

38. Chimenti F, Secci D, Bolasco A, et al. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem 2009;52:1935–42.

39. Viña D, Matos MJ, Yáñez M, et al. 3-substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer’s disease. Med Chem Commun 2012;3:213–8.

40. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.

41. Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Therap 2014;143:133–52.

42. Milczek E, Binda C, Rovida S, et al. The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J 2011;278:4860–9.

43. Moureau F, Wouters J, Vercauteren D, et al. A reversible monoamine oxidase inhibitor, toloxetine: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). Euro J Med Chem 1994;29:269–77.

44. Ramsay RR, Basile L, Maniquet A, et al. Parameters for irreversible inactivation of monoamine oxidase. Molecules 2020;25:5908.

45. Holt A, Berry M, Boulton A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO
active site, and effects thereby elicited. Neurotoxicology 2004;25:251–66.

46. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003;9:97–140.

47. Provost JC, Funck-Brentano C, Rovei V, et al. Pharmacokinetic and pharmacodynamic interaction between tolloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther 1992;52:384–93.

48. Chiou S-Y, Huang C-F, Hwang M-T, Lin G. Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene-di-N-substituted carbamates. J Biochem Mol Toxicol 2009;23:303–8.

49. Shen Q, Peng Q, Shao J, et al. Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. ChemInform 2006;37:1307–15.

50. Massoulié J. The polymorphism of cholinesterases and its physiological significance. Trends Biochem Sci 1980;5:160–4.

51. Silman I, Sussman J. Acetylcholinesterase: how is structure related to function? Chemico-Biol Interact 2008;175:3–10.

52. Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-[(4-benzylpiperazin-1-yl)ethyl]isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. DARU J Pharma Sci 2013;21:47.

53. Orhan I, Gulcan H. Coumarins: auspicious cholinesterase and monooxidase oxidase inhibitors. Curr Top Med Chem 2015;15:1673–82.

54. Kasumbwe KN, Venugopala K, Mohanlall V, Odhav B. Synthetic mono/di-halogenated coumarin derivatives and their anticancer properties. Anti-Cancer Agents Med Chem 2017;17:276–85.

55. Zeng X, Chen J, Deng X, et al. An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+-toxicity and GDNF neuroprotection. Neuropsychopharmacology 2006;31:2708–15.

56. Santos N, Martins N, Sisti F, et al. The neuroprotection of cannabidiol against MPP⁺/NADH-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson’s disease. Toxicol In Vitro 2015;30:231–40.

57. Zindo FT, Joubert J, Malan SF. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Med Chem 2015;7:609–29.

58. Bar-Am O, Amit T, Youdim MB, Weinreb O. Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. J Neural Transm 2016;123:125–35.

59. Kapp E, Visser H, Sampson S, et al. Versatility of 7-substituted coumarin molecules as antimycobacterial agents, neuronal enzyme inhibitors and neuroprotective agents. Molecules 2017;22:1644.

60. Storey E, Cappai R. The amyloid precursor protein of Alzheimer’s disease and the Abeta peptide. Neuropathol Appl Neurobiol 1999;25:81–97.

61. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 2016;8:595–608.

62. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.

63. Ranade DS, Bapat AM, Ramteke SN, et al. Thiosemicarbazone modification of 3-acetyl coumarin inhibits Aβ peptide aggregation and protect against Aβ-induced cytotoxicity. Eur J Med Chem 2016;121:803–9.

64. Prucooli L, Morroni F, Sita G, et al. Esculetin as a bifunctional antioxidant prevents and counteracts the oxidative stress and neuronal death induced by amyloid protein in SH-SYSY cells. Antioxidants 2020;9:551.

65. Chi T-Y, Wang L-H, Ji X-F, et al. Protective effect of xanthoceraside against β-amyloid-induced neurotoxicity in neuroblastoma SH-SYSY cells. J Asian Nat Prod Res 2013;15:1013–22.

66. Henríquez G, Mendez L, Varela-Ramirez A, et al. Neuroprotective effect of Brazilian on amyloid β (25-35)-induced pathology in a human neuroblastoma model. ACS Omega 2020;5:13785–92.

67. Wang H, Xu Y, Yan J, et al. Acteoside protects human neuroblastoma SH-SYSY cells against beta-amyloid-induced cell injury. Brain Res 2009;1283:139–47.

68. Kong M, Ba M. Protective effects of diazoxide against Aβ25-35-induced PC12 cell apoptosis due to prevention of endoplasmic reticulum stress. Neuroreport 2012;23:493–7.

69. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev 2014;66:334–95.

70. Matlock MK, Hughes TB, Dahlin JL, Swamidass SJ. Modeling small-molecule reactivity identifies promiscuous bioactive compounds. J Chem Inf Model 2018;58:1483–500.

71. Daina A, Michelin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7;42717.

72. Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016;11:1117–21.

73. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews 2002;34:47–54.

74. Ndomba FA, Maiyoh GKK, Tuel VC. Pharmacokinetic, physicochemical and medicinal properties of n-glycoside anti-cancer agent more potent than 2-deoxy-D-glucose in lung cancer cells. J Pharma Pharmacol 2019;7:165–76.